COM-701 is under clinical development by Compugen and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how COM-701’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
COM-701 is under development for the treatment of solid tumors including colorectal cancer, non-small cell lung cancer, ovarian cancer, triple negative breast cancer, multiple myeloma, PD1 refractory or relapsing head and neck squamous cell carcinoma including oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, paranasal sinus, nasopharyngeal, non-small cell lung cancer, colorectal cancer, endometrial cancer, primary peritoneal cancer and fallopian tube cancer. The drug candidate is a high affinity humanized IgG4 mAb. It is administered intravenously. It acts by targeting CGEN-15029/PVRIG, a B7/CD28 like immune checkpoint protein. The drug candidate is developed based on antibody therapeutic targets discovery platform and protein family members discovery platform.
Compugen is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s pipeline comprises COM701 and PVRIG, BAY 1905254, COM902, and TIGIT. Its drug development process includes target discovery, target validation and predictive discovery programs. The company offers predictive theories for the integration process containing biology knowledge, genome and proteome analysis and experimental and disease data, computational models, and novel and non-novel candidates. It operates in Israel, the US and Canada. Compugen is headquartered in Holon, Tel Aviv, Israel.
For a complete picture of COM-701’s drug-specific PTSR and LoA scores, buy the report here.